LR Health & Beauty SE Reports 2025 Preliminary Results and Plans Restructuring

LR Health & Beauty SE has announced its preliminary financial results for 2025, projecting an EBITDA of EUR 16 million, slightly below the previously expected range of EUR 17-20 million. Sales for the year are anticipated to reach EUR 277 million. Concurrently, a draft restructuring opinion by EY-Parthenon suggests significant improvements by 2028, with potential EBITDA reaching up to EUR 31.4 million and sales up to EUR 284.7 million in optimized scenarios.

The company is initiating discussions with shareholders and bondholders to explore financial restructuring. Proposed measures include a EUR 10 million equity contribution from shareholders and bondholder-approved amendments to the 2024/2028 bonds. This includes a 55% write-down of bond values, extending bond terms, deferring interest payments, and introducing cash sweep mechanisms. Bondholders are also offered participation in refinancing efforts.